BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21218110)

  • 1. The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells.
    Poljaková J; Eckschlager T; Hřebačková J; Hraběta J; Stiborová M
    Interdiscip Toxicol; 2008 Sep; 1(2):186-9. PubMed ID: 21218110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
    Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
    Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
    Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ellipticine cytotoxicity to cancer cell lines - a comparative study.
    Stiborová M; Poljaková J; Martínková E; Bořek-Dohalská L; Eckschlager T; Kizek R; Frei E
    Interdiscip Toxicol; 2011 Jun; 4(2):98-105. PubMed ID: 21753906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
    Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.
    Indra R; Černá T; Heger Z; Hraběta J; Wilhelm M; Dostálová S; Lengálová A; Martínková M; Adam V; Eckschlager T; Schmeiser HH; Arlt VM; Stiborová M
    Toxicology; 2019 May; 419():40-54. PubMed ID: 30914192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells.
    Hrabeta J; Groh T; Khalil MA; Poljakova J; Adam V; Kizek R; Uhlik J; Doktorova H; Cerna T; Frei E; Stiborova M; Eckschlager T
    Int J Oncol; 2015 Sep; 47(3):971-80. PubMed ID: 26134421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.
    Stiborová M; Rupertová M; Frei E
    Biochim Biophys Acta; 2011 Jan; 1814(1):175-85. PubMed ID: 20576524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.
    Cerna T; Hrabeta J; Eckschlager T; Frei E; Schmeiser HH; Arlt VM; Stiborová M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29304031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.
    Bedrnicek J; Vicha A; Jarosova M; Holzerova M; Cinatl J; Michaelis M; Cinatl J; Eckschlager T
    Neoplasma; 2005; 52(5):415-9. PubMed ID: 16151587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidation of an antitumor drug ellipticine by peroxidases.
    Poljaková J; Forsterová K; Sulc M; Frei E; Stiborová M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):449-53. PubMed ID: 16601808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
    Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
    Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
    Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
    Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells.
    Procházka P; Libra A; Zemanová Z; Hřebačková J; Poljaková J; Hraběta J; Bunček M; Stiborová M; Eckschlager T
    Cancer Sci; 2012 Feb; 103(2):334-41. PubMed ID: 22040216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.
    Frei E; Bieler CA; Arlt VM; Wiessler M; Stiborová M
    Biochem Pharmacol; 2002 Jul; 64(2):289-95. PubMed ID: 12123750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
    Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
    Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.
    Stiborova M; Rupertova M; Schmeiser HH; Frei E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2006 Jul; 150(1):13-23. PubMed ID: 16936898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression.
    Blaheta RA; Daher FH; Michaelis M; Hasenberg C; Weich EM; Jonas D; Kotchetkov R; Doerr HW; Cinatl J
    BMC Cancer; 2006 Dec; 6():294. PubMed ID: 17181871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
    Stiborová M; Rupertová M; Aimová D; Ryslavá H; Frei E
    Toxicology; 2007 Jul; 236(1-2):50-60. PubMed ID: 17482743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
    Stiborová M; Bieler CA; Wiessler M; Frei E
    Biochem Pharmacol; 2001 Dec; 62(12):1675-84. PubMed ID: 11755121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.